Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in people who are immune compromised.
"Although the risk to Americans from influenza A (H5) virus infection remains low, we're leaning forward with our ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback